The Oil & Gas Journal, first published in 1902, is the world's most widely read petroleum industry publication. OGJ delivers international oil and gas industry news; analysis of issues and events; practical technology for design, operation, and maintenance of oil and gas operations; and important statistics on energy markets and industry activity.

OGJ is edited to meet the needs of engineers, geoscientists, managers, and executives throughout the oil and gas industry. It is part of Endeavor Business Media, Nashville, Tenn., which also publishes Offshore Magazine.

Endeavor Business Media’s Petroleum Group also produces targeted e-Newsletters; hosts global conferences and exhibitions, seminars, and forums; and publishes directories, technical books, print and electronic databases, surveys, and maps.

Additional Information

Website & Technical Help

For help with subscription purchases or refunds, or trouble logging into the paid subscription content on www.ogj.com, please contact Customer Service at [email protected] or call 1-847-559-7598.

For more customer service information, please click here.

From Fighting Inflammation To Regenerating Cells: How Jupiter Neurosciences Is Putting The Pep Back In Our Step As We Age

By Meg Flippin Benzinga

Jupiter Neurosciences is a clinical-stage pharmaceutical company developing drugs to treat neuroinflammation, with a current focus on central nervous system (CNS) disorders such as Alzheimer's and Parkinson's, and rare diseases. The company also has a direct-to-consumer longevity product line called  Nugevia™, which is aimed at generating near-term revenue while maintaining momentum in its clinical pipeline. 

At the heart of Jupiter Neurosciences' business is JOTROL™, which is an enhanced orally administered resveratrol formulation designed and intended to deliver therapeutically relevant, safe levels of resveratrol. The company said a phase 1 trial showed it to achieve blood plasma levels 8-10-fold higher than naïve resveratrol.

“I like cash flow and biotech is not cash flow,” Rosen told Benzinga about the company’s direct-to-consumer line. “You hope you get good results, you raise some money and you hope for good results.” Nugevia's first three formulations target mitochondrial support, mental clarity and "beauty from within" and will be sold via a direct-to-consumer (DTC) model starting in the third quarter.  “The longevity and aging market is exploding,” says Rosen. 

Jupiter Neurosciences is going after CNS diseases and the longevity markets because of multi-functional benefits. On the one hand, it can reduce and potentially eliminate inflammation, which is key to treating brain diseases such as Alzheimer’s and Parkinson's, says Rosen. It can also increase mitochondria, which regenerate cells. 

Watch the full interview here: 
https://www.youtube.com/watch?v=RdPdpeSngww

Featured image from Shutterstock.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

This content was originally published on Benzinga. Read further disclosures here.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.